ACOEM released a position statement on marijuana legalization, emphasizing its opposition to wider consumption of the drug due to workplace safety concerns. The statement reads in part:
“Without measurable concentrations of psychoactive ingredients in marijuana-containing products, known potency of the active ingredient, delivery mechanism, or scientifically established dose or dosing schedule, it is impossible to use evidence-based methods to evaluate marijuana impairment in the workplace. While there is much we do not know about marijuana and other cannabinoids, there is enough current knowledge of their effects. In addition, there are enough acknowledged significant gaps in scientific evidence to raise concern and caution in the legislative process surrounding marijuana use.”
Read more here.